Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform

Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections

(2018) Elisa Uliassi et al.   ChemMedChem

Aryl thiosemicarbazones for the treatment of trypanosomatidic infections

(2018) Pasquale Linciano et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds

(2017) Chiara Borsari et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Neglected tropical diseases: progress towards addressing the chronic pandemic

(2017) David H Molyneux et al.   LANCET

Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity

(2017) Flavio Di Pisa et al.   MOLECULES

Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

(2017) Mark C. Field et al.   NATURE REVIEWS MICROBIOLOGY

Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs

(2016) Chiara Borsari et al.   JOURNAL OF MEDICINAL CHEMISTRY

Alkylphospholipids – A Promising Class of Chemotherapeutic Agents with a Broad Pharmacological Spectrum

(2016) Juliana De Almeida Pachioni et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Privileged scaffolds in lead generation

(2015) Hongyu Zhao et al.   Expert Opinion on Drug Discovery

A Phenotypic Screening Approach to Identify Anticancer Compounds Derived from Marine Fungi

(2014) Bernhard Ellinger et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Nifurtimox-Eflornithine Combination Therapy for Second-Stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières Experience in the Democratic Republic of the Congo

(2012) Emilie Alirol et al.   CLINICAL INFECTIOUS DISEASES

Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)

(2012) Peter GE Kennedy   LANCET NEUROLOGY

The Relevance of Higher Plants in Lead Compound Discovery Programs

(2011) A. Douglas Kinghorn et al.   JOURNAL OF NATURAL PRODUCTS

Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in mice

(2010) Natasha Sienkiewicz et al.   MOLECULAR MICROBIOLOGY

Development and validation of a cytochrome c-coupled assay for pteridine reductase 1 and dihydrofolate reductase

(2009) Emma J. Shanks et al.   ANALYTICAL BIOCHEMISTRY

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

(2009) Gerardo Priotto et al.   LANCET

Requirements for a lead compound to become a clinical candidate

(2008) Franz F Hefti   BMC NEUROSCIENCE

Antileishmanial Constituents of the Panamanian Endophytic FungusEdeniasp.

(2008) Sergio Martínez-Luis et al.   JOURNAL OF NATURAL PRODUCTS